search
Back to results

PRotEin Provision in Critical IllneSs (PRECISe)

Primary Purpose

Critical Illness, Intensive Care Unit Acquired Weakness

Status
Active
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
PRECISe protocol EN 8g protein/100kcal
PRECISe protocol EN 5g protein/100kcal
Sponsored by
Maastricht University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Critical Illness focused on measuring Enteral Nutrition, Dietary Proteins, Respiratory failure, Catabolism

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult (18 years or above) patient admitted to the ICU
  • Unplanned ICU admission
  • Invasive mechanical ventilation initiated <24 hours of ICU admission
  • Expected ICU stay on ventilator support of 3 days or more

Exclusion Criteria:

  • Contraindication for enteral nutrition
  • Moribund or expected withholding of treatment
  • Kidney failure AND 'no-dialysis'-code on admission
  • Hepatic encephalopathy.(West Haven grade 3 or 4)
  • Body-mass index < 18 kg/m2

Sites / Locations

  • UZ Brussel
  • Ziekenhuis Oost-Limburg
  • AZ Groeninge
  • CHR de la Citadelle
  • CHU Liège
  • Catharina Ziekenhuis Eindhoven
  • Gelderse Vallei Ede
  • Medisch Spectrum Twente
  • Zuyderland Medisch Centrum
  • Maastricht Universtair Medisch Centrum

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

PRECISe protocol EN (8g protein/100kcal)

PRECISe protocol EN (5g protein/100kcal)

Arm Description

Enteral (EN) feed with 8 grams protein per 100 kcal (2.0 g/kg/day protein when on target). The caloric goal is 25 kcal/kg/day to be reached on day 4 of ICU admission.

Enteral (EN) feed with 5 grams protein per 100 kcal (1.3 g/kg/day protein when on target). The caloric goal is 25 kcal/kg/day to be reached on day 4 of ICU admission.

Outcomes

Primary Outcome Measures

Health Related Quality of Life (HRQL)
Overall difference in EQ-5D single summary index between intervention and control group over the three time-points combined, corrected for baseline. A higher summary index indicates better Health related Quality of Life.

Secondary Outcome Measures

Overall survival
Overall survival
Health-related Quality of Life - SF-36
Short Form 36 (SF-36), ranging from 0 to 100. A higher score indicates a better Health-related Quality of Life.
Mental health status - anxiety/depression
Hospital Anxiety and Depression Scale (HADS), ranging from 0 to 42. Questions 1, 3, 5, 7, 9, 11 and 13 measure symptoms of anxiety (range: 0-21). Questions 2, 4, 6, 8, 10, 12 and 14 measure symptoms of depression (range: 0-21). Higher scores indicate worse symptoms of anxiety and depression.
Pain intensity
EQ-5D pain question, ranging from 1 to 5, corrected for baseline. A higher score indicates a more severe perception of pain.
Self-reported health
EQ-5D Visual Analogue Scale (EQ-VAS), ranging from 0 to 100. A higher score indicates a better self-reported health.
Mental health status - post-traumatic stress
Impact of Event Scale Revised (IES-R), ranging from 0 to 88. A higher score indicates worse symptoms of Post-Traumatic Stress Disorder.
Physical function - 6-minute walk test
6-minute walk test. Data collected during 6-minute walk test are pre- and post-test saturation and pulse and total distance walked with or without the use of any aids.
Muscle and nerve function - MRC-sum score
Medical Research Council (MRC-)sum score, ranging from 0 to 60. A higher score indicates better muscle and nerve function.
Muscle and nerve function - handgrip strength
Handgrip strength, assessed via a hand dynamometer and measured in kilograms (kg).

Full Information

First Posted
October 23, 2020
Last Updated
April 17, 2023
Sponsor
Maastricht University Medical Center
Collaborators
Ziekenhuis Oost-Limburg, Zuyderland Medisch Centrum, Gelderse Vallei Hospital, Medisch Spectrum Twente, Centre Hospitalier Universitaire de Liege, Centre Hospitalier Régional de la Citadelle, Universitair Ziekenhuis Brussel, General Hospital Groeninge, Catharina Ziekenhuis Eindhoven
search

1. Study Identification

Unique Protocol Identification Number
NCT04633421
Brief Title
PRotEin Provision in Critical IllneSs
Acronym
PRECISe
Official Title
The Impact of High Versus Standard Enteral Protein Provision on Functional Recovery Following Intensive Care Admission: a Randomized Controlled, Multicenter, Parallel Group Trial in Mechanically Ventilated, Critically Ill Patients
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 19, 2020 (Actual)
Primary Completion Date
October 2023 (Anticipated)
Study Completion Date
October 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maastricht University Medical Center
Collaborators
Ziekenhuis Oost-Limburg, Zuyderland Medisch Centrum, Gelderse Vallei Hospital, Medisch Spectrum Twente, Centre Hospitalier Universitaire de Liege, Centre Hospitalier Régional de la Citadelle, Universitair Ziekenhuis Brussel, General Hospital Groeninge, Catharina Ziekenhuis Eindhoven

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Rapid skeletal muscle wasting during critical illness had a detrimental impact on both short and long term outcomes following ICU admission. Increased dietary protein delivery might attenuate skeletal muscle wasting and its subsequent effects on post-ICU function. The investigators will conduct a 935 patient, randomised controlled, quadruple blinded parallel group trial to determine whether enteral nutrition with increased protein content in mechanically ventilated, critically ill patients is able to improve functional recovery.
Detailed Description
ICU-acquired weakness (ICU-AW) is frequent among ICU survivors and negatively affects both short and long term outcomes. ICU-AW is the consequence of the body's reserves being depleted during critical illness and results in severe skeletal muscle wasting during the first week of ICU admission.Therefore, measures aimed at preserving muscle mass during critical illness and improving recovery after ICU discharge are urgently needed. Retrospective observational cohort studies suggest that the administration of high protein nutrition is associated with improved survival and outcome. Current ICU guidelines recommend dietary protein delivery at 1.3 g/kg/day (ESPEN), or even up to 2.0 g/kg/day (ASPEN). However, strong prospective clinical evidence on the effectiveness and safety of high enteral protein delivery is lacking and urgently awaited. Therefore, the aim of the present study is to investigate the effect of high versus standard protein provision on the functional recovery of critically ill patients. The focus on functional, patient-centered outcomes rather than traditional clinical endpoints like mortality is an important aspect and strength of the study. Previous nutritional intervention studies focusing primarily on improving mortality have repeatedly shown no effect. Therefore, it is nowadays increasingly recognized to move primary ICU trial endpoints away from classical outcomes, such as survival or length of stay, towards more functional outcomes, in line with the underlying pathophysiology.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Illness, Intensive Care Unit Acquired Weakness
Keywords
Enteral Nutrition, Dietary Proteins, Respiratory failure, Catabolism

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Study feeds will be blinded. Dosing of intervention will be volume based, with the same volume targets for both groups. Differences in composition of study feeds will result in differences in protein intake at similar volume administration.
Allocation
Randomized
Enrollment
935 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PRECISe protocol EN (8g protein/100kcal)
Arm Type
Experimental
Arm Description
Enteral (EN) feed with 8 grams protein per 100 kcal (2.0 g/kg/day protein when on target). The caloric goal is 25 kcal/kg/day to be reached on day 4 of ICU admission.
Arm Title
PRECISe protocol EN (5g protein/100kcal)
Arm Type
Active Comparator
Arm Description
Enteral (EN) feed with 5 grams protein per 100 kcal (1.3 g/kg/day protein when on target). The caloric goal is 25 kcal/kg/day to be reached on day 4 of ICU admission.
Intervention Type
Dietary Supplement
Intervention Name(s)
PRECISe protocol EN 8g protein/100kcal
Intervention Description
Enteral feed containing 8g protein/100kcal
Intervention Type
Dietary Supplement
Intervention Name(s)
PRECISe protocol EN 5g protein/100kcal
Intervention Description
Enteral feed containing 5g protein/100kcal
Primary Outcome Measure Information:
Title
Health Related Quality of Life (HRQL)
Description
Overall difference in EQ-5D single summary index between intervention and control group over the three time-points combined, corrected for baseline. A higher summary index indicates better Health related Quality of Life.
Time Frame
Day 0, Day 30, 90 and 180 after index ICU admission.
Secondary Outcome Measure Information:
Title
Overall survival
Description
Overall survival
Time Frame
Day 30, 90 and 180 after ICU admission
Title
Health-related Quality of Life - SF-36
Description
Short Form 36 (SF-36), ranging from 0 to 100. A higher score indicates a better Health-related Quality of Life.
Time Frame
Day 30, 90 and 180 after ICU admission
Title
Mental health status - anxiety/depression
Description
Hospital Anxiety and Depression Scale (HADS), ranging from 0 to 42. Questions 1, 3, 5, 7, 9, 11 and 13 measure symptoms of anxiety (range: 0-21). Questions 2, 4, 6, 8, 10, 12 and 14 measure symptoms of depression (range: 0-21). Higher scores indicate worse symptoms of anxiety and depression.
Time Frame
Day 30, 90 and 180 after ICU admission
Title
Pain intensity
Description
EQ-5D pain question, ranging from 1 to 5, corrected for baseline. A higher score indicates a more severe perception of pain.
Time Frame
Day 0, Day 30, 90 and 180 after index ICU admission
Title
Self-reported health
Description
EQ-5D Visual Analogue Scale (EQ-VAS), ranging from 0 to 100. A higher score indicates a better self-reported health.
Time Frame
Day 0, Day 30, 90 and 180 after index ICU admission
Title
Mental health status - post-traumatic stress
Description
Impact of Event Scale Revised (IES-R), ranging from 0 to 88. A higher score indicates worse symptoms of Post-Traumatic Stress Disorder.
Time Frame
Day 30, 90 and 180 after ICU admission.
Title
Physical function - 6-minute walk test
Description
6-minute walk test. Data collected during 6-minute walk test are pre- and post-test saturation and pulse and total distance walked with or without the use of any aids.
Time Frame
Day 30, 90 and 180 after ICU admission
Title
Muscle and nerve function - MRC-sum score
Description
Medical Research Council (MRC-)sum score, ranging from 0 to 60. A higher score indicates better muscle and nerve function.
Time Frame
Day 30, 90 and 180 after ICU admission
Title
Muscle and nerve function - handgrip strength
Description
Handgrip strength, assessed via a hand dynamometer and measured in kilograms (kg).
Time Frame
Day 30, 90 and 180 after ICU admission.
Other Pre-specified Outcome Measures:
Title
Duration of mechanical ventilation
Description
Number of days on invasive mechanical ventilation.
Time Frame
During index ICU stay, up to 90 days.
Title
Duration of index ICU stay
Description
Number of days in ICU.
Time Frame
During index ICU stay, up to 90 days.
Title
Duration of index hospital stay
Description
Number of days in hospital.
Time Frame
From date of randomization until the date of index hospital discharge, assessed up to 6 months.
Title
Hospital mortality
Description
Hospital mortality
Time Frame
From index ICU admission until index hospital discharge, assessed up to 6 months.
Title
60-day mortality
Description
Mortality at 60 days after ICU admission.
Time Frame
From index ICU admission until day 60.
Title
Time-to-discharge-alive
Description
Days until live hospital discharge
Time Frame
From index ICU admission until index hospital discharge, assessed up to 6 months.
Title
Nutritional adequacy
Description
Ratio between total amount of calories and grams of protein actually received by patients and prescribed during treatment period.
Time Frame
From index ICU admission until index ICU discharge, assessed up to 6 months.
Title
Administration of prokinetics
Description
Number of patients who received a prokinetic and number of days on it.
Time Frame
During index ICU stay, up to 90 days.
Title
Incidence of gastrointestinal intolerance/symptoms
Description
Number of patients that experienced gastrointestinal intolerance or symptoms at any time during index ICU stay, i.e. vomiting, ischemia, diarrhea, abdominal distention, gastric paresis, bleeding/ulcer.
Time Frame
During index ICU stay, up to 90 days.
Title
Incidence of ICU-readmission
Description
Number of patients readmitted to the ICU during index hospital stay and number of readmissions per patient.
Time Frame
From date of randomization until the date of index hospital discharge, assessed up to 6 months.
Title
Incidence of ICU-acquired infections
Description
Number of patients who contracted an ICU-acquired infection.
Time Frame
During index ICU stay, up to 90 days.
Title
Incidence of acute kidney injury
Description
Number of patients with Acute Kidney Injury (AKI), defined as a serum creatinine level higher than 2 times baseline level.
Time Frame
During index ICU stay, up to 90 days.
Title
Incidence and duration of renal replacement therapy
Description
Number of patients who received renal replacement therapy and days on it.
Time Frame
During index ICU stay, up to 90 days.
Title
Incidence of hepatic dysfunction
Description
Number of patients with hepatic dysfunction, defined as a total bilirubin level > 3mg/dL.
Time Frame
During index ICU stay, up to 90 days.
Title
Maximum and mean SOFA score
Description
Sequential Organ Failure Assessment score (SOFA), ranging from 0 to 24. A higher score indicates more severe multi-organ failure.
Time Frame
During index ICU stay, up to 90 days.
Title
Difference in mobilization treatment
Description
Number of days and degree of daily mobilization (passive/active, in-bed cycling etc).
Time Frame
During index ICU stay, up to 90 days.
Title
Difference in frailty
Description
Rockwood Clinical Frailty Scale, ranging from 1 to 9, corrected for baseline. A higher score indicates a more severe degree of frailty.
Time Frame
Day 0, Day 30, 90 and 180 after index ICU admission.
Title
Domain data EQ-5D
Description
Scores of subdomains of EQ-5D, ranging from 1 to 5. A higher score indicates a higher severity level on that subdomain.
Time Frame
Day 30, 90 and 180 after ICU admission.
Title
Destination of hospital discharge
Description
Destination of hospital discharge (home, rehabilitation center, care facility etc).
Time Frame
Follow-up until 180 days after index ICU admission.
Title
Length of stay at rehabilitation facility
Description
Number of days at rehabilitation center.
Time Frame
Follow-up until 180 days after index ICU admission.
Title
Time to return to work
Description
Number of days between ICU admission and return to work.
Time Frame
Follow-up until 180 days after index ICU admission.
Title
Health economic analysis
Description
Total health care costs.
Time Frame
From index ICU admission until 180 days.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult (18 years or above) patient admitted to the ICU Unplanned ICU admission Invasive mechanical ventilation initiated <24 hours of ICU admission Expected ICU stay on ventilator support of 3 days or more Exclusion Criteria: Contraindication for enteral nutrition Moribund or expected withholding of treatment Kidney failure AND 'no-dialysis'-code on admission Hepatic encephalopathy.(West Haven grade 3 or 4) Body-mass index < 18 kg/m2
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marcel CG van de Poll, MD, PhD
Organizational Affiliation
Maastricht UMC+
Official's Role
Principal Investigator
Facility Information:
Facility Name
UZ Brussel
City
Brussel
Country
Belgium
Facility Name
Ziekenhuis Oost-Limburg
City
Genk
ZIP/Postal Code
3600
Country
Belgium
Facility Name
AZ Groeninge
City
Kortrijk
Country
Belgium
Facility Name
CHR de la Citadelle
City
Liège
Country
Belgium
Facility Name
CHU Liège
City
Liège
Country
Belgium
Facility Name
Catharina Ziekenhuis Eindhoven
City
Eindhoven
State/Province
Noord-Brabant
ZIP/Postal Code
5623 EJ
Country
Netherlands
Facility Name
Gelderse Vallei Ede
City
Ede
Country
Netherlands
Facility Name
Medisch Spectrum Twente
City
Enschede
Country
Netherlands
Facility Name
Zuyderland Medisch Centrum
City
Heerlen
Country
Netherlands
Facility Name
Maastricht Universtair Medisch Centrum
City
Maastricht
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
28537429
Citation
Needham DM, Sepulveda KA, Dinglas VD, Chessare CM, Friedman LA, Bingham CO 3rd, Turnbull AE. Core Outcome Measures for Clinical Research in Acute Respiratory Failure Survivors. An International Modified Delphi Consensus Study. Am J Respir Crit Care Med. 2017 Nov 1;196(9):1122-1130. doi: 10.1164/rccm.201702-0372OC.
Results Reference
background

Learn more about this trial

PRotEin Provision in Critical IllneSs

We'll reach out to this number within 24 hrs